Clinical Trials
Numerous clinical trials spanning Early Phase 1 through Phase 4 investigate digoxin across diverse indications, ranging from pharmacokinetic evaluations in healthy subjects to therapeutic interventions for acute heart failure, melanoma, HIV infections, and fetal procedures. Sponsored by academic institutions and major pharmaceutical companies, these studies encompass various recruitment statuses, including completed, actively recruiting, terminated, and withdrawn protocols.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06322017 | RECRUITING | Atrial Fibrillation |
Nantes University Hospital |
2024-04-09 | |
| NCT06588699 | RECRUITING | NASH; NAFLD; MASH - Metabolic Dysfunction-Associated Steatohepatitis; Mash; MASH With Fibrosis; MASLD; Fatty Liver Disease; Fatty Liver Disease, Nonalcoholic |
Yale University |
2025-06-05 | PHASE2 |
| NCT06030622 | RECRUITING | Pancreatic Cancer Metastatic |
State University of New York - Downstate Medical Center |
2024-04-17 | PHASE1; PHASE2 |
| NCT06240403 | NOT_YET_RECRUITING | Heart Failure, Systolic; Diabetes Mellitus, Type 2 |
University of Leeds |
2025-09-01 | PHASE2 |
| NCT07321509 | RECRUITING | Acute Heart Failure (AHF) |
Hospital General de Agudos "Dr. Cosme Argerich" |
2025-12-16 | PHASE4 |
| NCT03016819 | RECRUITING | Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma |
Advenchen Laboratories, LLC |
2017-08-15 | PHASE3 |
| NCT07272902 | RECRUITING | Atrial Fibrillation (AF); Heart Failure With Mildly Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction (HFPEF); Rate Control; Rhythm Control |
Nova Scotia Health Authority |
2026-01-01 | |
| NCT05614739 | RECRUITING | Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms |
Eli Lilly and Company |
2023-01-12 | PHASE1 |
| NCT07339722 | RECRUITING | Healthy |
Eli Lilly and Company |
2026-01-15 | PHASE1 |
| NCT06701812 | RECRUITING | Medulloblastoma; Medulloblastoma, Non-WNT/Non-SHH |
H. Lee Moffitt Cancer Center and Research Institute |
2026-01-15 | PHASE2 |
| NCT07025850 | NOT_YET_RECRUITING | Colorectal Carcinoma |
Fudan University |
2025-08-01 | PHASE1; PHASE2 |
| NCT03889795 | ACTIVE_NOT_RECRUITING | Advanced Pancreatic Cancer; Advanced Solid Tumor |
Danae Hamouda, MD |
2019-06-05 | PHASE1 |
| NCT07550816 | RECRUITING | Overweight,Obesity |
Beijing QL Biopharmaceutical Co.,Ltd |
2026-05-27 | PHASE1 |
| NCT07502001 | NOT_YET_RECRUITING | Overweight; Obesity |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2026-04-08 | PHASE1 |
| NCT07785934 | RECRUITING | Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics |
The United Bio-Technology (Hengqin) Co., Ltd. |
2026-05-27 | PHASE1 |
| NCT07008144 | NOT_YET_RECRUITING | Drug-Related Side Effects and Adverse Reaction; Digoxin Overdose |
Consorci Sanitari de l'Alt Penedès i Garraf |
2025-12 | |
| NCT07565441 | NOT_YET_RECRUITING | ADPKD (Autosomal Dominant Polycystic Kidney Disease) |
Jemincare |
2026-05-11 | PHASE1 |
| NCT07567781 | COMPLETED | Healthy Volunteers |
AbbVie |
2026-04-30 | PHASE1 |
| NCT07128888 | RECRUITING | Obesity or Overweight |
Gan & Lee Pharmaceuticals. |
2025-11-17 | PHASE1 |
| NCT07570082 | COMPLETED | Healthy Volunteers |
Crinetics Pharmaceuticals Inc. |
2026-05-28 | PHASE1 |
| NCT07118215 | COMPLETED | Healthy Volunteers |
Karuna Therapeutics, Inc., a Bristol Myers Squibb company |
2025-09-29 | PHASE1 |
| NCT06717269 | COMPLETED | Healthy Volunteer |
Nurix Therapeutics, Inc. |
2024-11-30 | PHASE1 |
| NCT06613477 | COMPLETED | Single-ventricle; Infant Conditions; Infant, Newborn, Diseases; Infant, Premature, Diseases |
Duke University |
2024-10-10 | PHASE1; PHASE2 |
| NCT07047209 | COMPLETED | ALS (Amyotrophic Lateral Sclerosis) |
Massachusetts General Hospital |
2025-05-27 | PHASE2 |
| NCT07269756 | COMPLETED | Obesity; Overweight |
Shandong Suncadia Medicine Co., Ltd. |
2025-12-07 | PHASE1 |
| NCT07223671 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2025-12-31 | PHASE1 |
| NCT06899061 | ACTIVE_NOT_RECRUITING | Advanced Solid Malignancies |
AstraZeneca |
2025-03-25 | PHASE1 |
| NCT07362030 | ACTIVE_NOT_RECRUITING | Obesity |
Guangdong Raynovent Biotech Co., Ltd |
2025-04-14 | PHASE1 |
| NCT06981299 | COMPLETED | Healthy |
Protego Biopharma Pty Ltd |
2025-05-29 | PHASE1 |
| NCT07066722 | COMPLETED | HIV Infections |
ViiV Healthcare |
2025-07-07 | PHASE1 |
| NCT07215260 | COMPLETED | Healthy |
Boehringer Ingelheim |
2025-11-05 | PHASE1 |
| NCT03783429 | COMPLETED | Heart Failure |
University Medical Center Groningen |
2020-07-01 | PHASE4 |
| NCT05287191 | UNKNOWN | Atrial Fibrillation New Onset |
Sunnybrook Health Sciences Centre |
2022-01-05 | PHASE3 |
| NCT06821594 | ENROLLING_BY_INVITATION | Cutaneous Warts |
Jinnah Postgraduate Medical Centre |
2025-04-01 | EARLY_PHASE1 |
| NCT05828303 | WITHDRAWN | Advanced Solid Tumor; Metastatic Solid Tumor |
Turning Point Therapeutics, Inc. |
2024-11-15 | PHASE1 |
| NCT02544815 | UNKNOWN | Acute Heart Failure |
University of Monastir |
2023-05-01 | PHASE3 |
| NCT05469204 | COMPLETED | Transgender Persons |
University of Washington |
2022-11-01 | PHASE4 |
| NCT07065058 | COMPLETED | Obesity &Amp; Overweight |
Vincentage Pharma Co., Ltd |
2025-07-01 | PHASE1 |
| NCT06921941 | COMPLETED | Healthy Volunteer Study |
Atea Pharmaceuticals, Inc. |
2025-04-08 | PHASE1 |
| NCT05014087 | TERMINATED | Acute Alcoholic Hepatitis; Chemical and Drug Induced Liver Injury; Alcohol-Induced Disorders; Steatohepatitis Caused by Ingestible Alcohol |
Yale University |
2021-10-08 | PHASE2 |
| NCT06723691 | COMPLETED | Type 2 Diabetes |
Fujian Shengdi Pharmaceutical Co., Ltd. |
2024-12-18 | PHASE1 |
| NCT06949124 | COMPLETED | Endometriosis; Uterine Fibroids; Assisted Reproduction |
Jiangsu HengRui Medicine Co., Ltd. |
2025-04-28 | PHASE1 |
| NCT06813924 | COMPLETED | Healthy Volunteers Sickle Cell Disease, Thalassemia |
Novo Nordisk A/S |
2025-02-06 | PHASE1 |
| NCT04141995 | TERMINATED | Pancreas Cancer; Adenocarcinoma of the Pancreas |
University of Nebraska |
2021-02-12 | PHASE2 |
| NCT06793943 | COMPLETED | Healthy Volunteers |
Takeda |
2025-01-23 | PHASE1 |
| NCT07307131 | COMPLETED | Cutaneous Warts; Human Papilloma Virus (HPV) |
Benha University |
2024-09-01 | PHASE2 |
| NCT06601517 | NOT_YET_RECRUITING | Healthy Adult Subject; Overweight Subject |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2024-10 | PHASE1 |
| NCT06416800 | COMPLETED | Healthy Participants |
Incyte Corporation |
2024-06-19 | PHASE1 |
| NCT06503679 | COMPLETED | Healthy |
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company |
2024-07-16 | PHASE1 |
| NCT06657404 | RECRUITING | Atrial Fibrillation (AF) |
Yumei Xue |
2024-10-23 | |
| NCT06677957 | COMPLETED | Healthy Participants |
Genentech, Inc. |
2024-11-06 | PHASE1 |
| NCT05741372 | COMPLETED | Liver Cirrhosis |
Boehringer Ingelheim |
2023-09-07 | |
| NCT04893629 | TERMINATED | Cardiomyopathy |
Damascus University |
2021-05-20 | |
| NCT06597760 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2024-10-07 | PHASE1 |
| NCT06575933 | COMPLETED | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2024-09-03 | PHASE1 |
| NCT06186622 | COMPLETED | Healthy; Obese; Overweight |
Eli Lilly and Company |
2024-01-02 | PHASE1 |
| NCT05738291 | COMPLETED | Healthy |
Boehringer Ingelheim |
2023-05-01 | PHASE1 |
| NCT06348290 | UNKNOWN | Solid Tumor, Adult |
Jemincare |
2024-04-01 | PHASE1 |
| NCT05926180 | COMPLETED | Non-small Cell Lung Cancer |
Dizal Pharmaceuticals |
2023-07-31 | PHASE1 |
| NCT03810417 | COMPLETED | Acute Kidney Injury |
University of Maryland, Baltimore |
2019-07-22 | PHASE4 |
| NCT03433833 | WITHDRAWN | Polycythemia; Familial; Erythrocytosis; Familial; VHL Gene Mutation; HIF-2alpha Erythrocytosis; PHD2 Erythrocytosis; Chuvash Erythrocytosis |
University of Illinois at Chicago |
2019-11-10 | PHASE1 |
| NCT06293742 | COMPLETED | Type 2 Diabetes Mellitus |
Eccogene |
2024-02-08 | PHASE1 |
| NCT06247748 | COMPLETED | Diabetes Mellitus, Type 2; Overweight |
Beijing Dongfang Biotech Co., Ltd. |
2023-10-19 | PHASE1 |
| NCT06111521 | COMPLETED | Healthy |
Eli Lilly and Company |
2023-10-27 | PHASE1 |
| NCT02624765 | COMPLETED | Fetal Atrial Flutter Without Hydrops; Fetal Supraventricular Tachycardia Without Hydrops; Fetal Supraventricular Tachycardia With Hydrops |
Edgar Jaeggi |
2016-02 | PHASE3 |
| NCT06162169 | COMPLETED | Healthy Subjects |
Allist Pharmaceuticals, Inc. |
2023-11-25 | PHASE1 |
| NCT06105255 | COMPLETED | Healthy Male |
InventisBio Co., Ltd |
2023-05-24 | PHASE1 |
| NCT06625827 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2023-11-07 | PHASE1 |
| NCT06335134 | COMPLETED | Healthy Volunteers |
Hangzhou Sciwind Biosciences Co., Ltd. |
2023-07-14 | PHASE1 |
| NCT06118684 | COMPLETED | Chronic Obstructive Pulmonary Disease Exacerbation; COPD |
EpiEndo Pharmaceuticals |
2023-10-23 | PHASE1 |
| NCT03928210 | COMPLETED | Breast Cancer; Circulating Tumor Cells (CTCs) |
University Hospital, Basel, Switzerland |
2020-07-08 | EARLY_PHASE1 |
| NCT06092931 | COMPLETED | Healthy Participants |
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company |
2023-10-16 | PHASE1 |
| NCT05954624 | COMPLETED | Drug Drug Interaction |
Guangdong Raynovent Biotech Co., Ltd |
2023-07-10 | PHASE1 |
| NCT05599971 | UNKNOWN | Plantar Wart |
Zagazig University |
2023-02-22 | |
| NCT05789342 | COMPLETED | Healthy Volunteers |
Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
2023-02-15 | PHASE1 |
| NCT05852769 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2023-05-31 | PHASE1 |
| NCT05815680 | COMPLETED | Overweight Subjects; Obese Subjects |
Innovent Biologics (Suzhou) Co. Ltd. |
2023-04-06 | PHASE1 |
| NCT05768360 | COMPLETED | Healthy Male Subjects |
AstraZeneca |
2023-04-25 | PHASE1 |
| NCT05507775 | COMPLETED | Non-Medullary Thyroid Carcinoma |
Radboud University Medical Center |
2022-12-06 | |
| NCT05694221 | COMPLETED | Healthy Volunteers |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
2023-03-20 | PHASE1 |
| NCT05763459 | COMPLETED | Healthy |
Calico Life Sciences LLC |
2023-03-24 | PHASE1 |
| NCT03559868 | COMPLETED | Inflammatory Response |
Yale University |
2021-03-01 | PHASE1 |
| NCT05541471 | COMPLETED | Pain |
Vertex Pharmaceuticals Incorporated |
2022-09-22 | PHASE1 |
| NCT05540600 | UNKNOWN | Atrial Fibrillation; Left Atrial Rhythm |
University of Monastir |
2022-09-12 | PHASE3 |
| NCT04887194 | COMPLETED | Advanced Solid Tumor |
Mirati Therapeutics Inc. |
2021-04-08 | PHASE1 |
| NCT04216693 | WITHDRAWN | Nonalcoholic Steatohepatitis |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2020-06-01 | PHASE2 |
| NCT05389722 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2022-06-09 | PHASE1 |
| NCT05444556 | COMPLETED | Healthy |
Eli Lilly and Company |
2022-07-07 | PHASE1 |
| NCT05526911 | COMPLETED | Pulmonary Disease; Tuberculosis, Pulmonary; Tuberculosis; Multi Drug Resistant Tuberculosis; Drug Sensitive Tuberculosis; Drug-resistant Tuberculosis; Mycobacterium Tuberculosis Infection |
Global Alliance for TB Drug Development |
2022-06-30 | PHASE1 |
| NCT05395117 | COMPLETED | Healthy Participants |
AstraZeneca |
2022-06-30 | PHASE1 |
| NCT05520658 | UNKNOWN | Plantar Wart |
Sohag University |
2022-07-01 | |
| NCT04778787 | COMPLETED | Congestive Heart Failure |
I.M. Sechenov First Moscow State Medical University |
2021-01-01 | PHASE4 |
| NCT05273775 | COMPLETED | Chronic Hepatitis B |
Jiangsu HengRui Medicine Co., Ltd. |
2022-04-29 | PHASE1 |
| NCT04513509 | COMPLETED | Atrial Fibrillation; Rate Control; Cardiopulmonary Exercise Test |
National Taiwan University Hospital |
2020-10-21 | |
| NCT03261570 | COMPLETED | Postural Orthostatic Tachycardia Syndrome (POTS); POTS; Orthostatic Intolerance |
New York Medical College |
2017-07-01 | EARLY_PHASE1 |
| NCT04834557 | COMPLETED | Rheumatoid Arthritis |
Tanta University |
2021-11-01 | PHASE2 |
| NCT04972396 | COMPLETED | NASH - Nonalcoholic Steatohepatitis |
Altimmune, Inc. |
2021-09-15 | PHASE1 |
| NCT03718273 | COMPLETED | Atrial Fibrillation; Heart Diseases |
Adolfo Fontenla |
2018-10-19 | PHASE3 |
| NCT05137626 | COMPLETED | Healthy Volunteers Study |
Atea Pharmaceuticals, Inc. |
2021-11-03 | PHASE1 |
| NCT05064488 | COMPLETED | Healthy |
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
2021-10-04 | PHASE1 |
| NCT05045313 | COMPLETED | Healthy Subjects |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2021-10-20 | PHASE1 |
| NCT04621669 | COMPLETED | Drug-drug Interaction,SHR3680 |
Jiangsu HengRui Medicine Co., Ltd. |
2021-01-08 | PHASE1 |
| NCT05357911 | COMPLETED | Solid Tumor |
Nuvation Bio Inc. |
2021-07-13 | PHASE1 |
| NCT04206488 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2020-01-09 | PHASE1 |
| NCT06194214 | COMPLETED | Healthy |
Eli Lilly and Company |
2021-03-11 | PHASE1 |
| NCT04268394 | COMPLETED | Healthy Volunteer |
Celgene |
2020-03-13 | PHASE1 |
| NCT04322552 | COMPLETED | Advanced Solid Tumor |
Jiangsu HengRui Medicine Co., Ltd. |
2020-03-12 | PHASE1 |
| NCT04425902 | COMPLETED | HIV Infections |
ViiV Healthcare |
2020-12-16 | PHASE1 |
| NCT06546215 | COMPLETED | Heart Failure |
Xiangya Hospital of Central South University |
2020-07-05 | PHASE1 |
| NCT04590937 | COMPLETED | Healthy |
Boehringer Ingelheim |
2020-10-20 | PHASE1 |
| NCT04308031 | UNKNOWN | Atrial Fibrillation; Ivabradine; Heart Failure |
Chun-Yao Huang |
2018-08-26 | PHASE3 |
| NCT04094519 | COMPLETED | Prostate Cancer |
Astellas Pharma Global Development, Inc. |
2020-01-27 | PHASE1 |
| NCT04493931 | COMPLETED | Infections, Bacterial |
GlaxoSmithKline |
2020-08-14 | PHASE1 |
| NCT03008616 | TERMINATED | Severe Preeclampsia |
AMAG Pharmaceuticals, Inc. |
2017-04-12 | PHASE2; PHASE3 |
| NCT04709081 | COMPLETED | Healthy |
Alexion Pharmaceuticals, Inc. |
2019-12-22 | PHASE1 |
| NCT04231435 | COMPLETED | Healthy Volunteers |
Celgene |
2019-12-18 | PHASE1 |
| NCT05598281 | COMPLETED | Healthy Participants |
Amgen |
2019-11-05 | PHASE1 |
| NCT03684772 | UNKNOWN | Actinic Keratosis |
Maruho Co., Ltd. |
2018-10-22 | PHASE2 |
| NCT04008186 | COMPLETED | Healthy Adult Subjects |
Biogen |
2019-06-14 | PHASE1 |
| NCT03856970 | COMPLETED | Healthy Volunteers |
Ironwood Pharmaceuticals, Inc. |
2019-03-11 | PHASE1 |
| NCT02906800 | UNKNOWN | Head and Neck Cancer |
Assistance Publique - Hôpitaux de Paris |
2017-01 | PHASE1; PHASE2 |
| NCT03909529 | COMPLETED | Drug Drug Interaction |
CMP Development, LLC |
2019-03-10 | PHASE1 |
| NCT02391337 | COMPLETED | Permanent Atrial Fibrillation |
University of Birmingham |
2016-12-20 | PHASE4 |
| NCT03113071 | TERMINATED | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Fox Chase Cancer Center |
2017-06-02 | PHASE1; PHASE2 |
| NCT02212639 | UNKNOWN | Kaposi' s Sarcoma; Classic Kaposi' s Sarcoma; Endemic Kaposi' s Sarcoma; Lymph Angio Proliferations |
Assistance Publique - Hôpitaux de Paris |
2014-09 | PHASE2 |
| NCT03723395 | COMPLETED | Drug-drug Interaction |
Seagen Inc. |
2018-09-17 | PHASE1 |
| NCT02248753 | COMPLETED | Atrial Fibrillation |
Maastricht University Medical Center |
2014-10 | |
| NCT03334240 | TERMINATED | HPV-Induced Genital Lesions |
Maruho Co., Ltd. |
2017-10-05 | PHASE2 |
| NCT03801759 | COMPLETED | Drug Interaction Potentiation |
Akebia Therapeutics |
2018-07-20 | PHASE1 |
| NCT03363815 | COMPLETED | Heathy Volunteer |
Celgene |
2017-12-04 | PHASE1 |
| NCT03136068 | COMPLETED | Abortion |
University of California, San Francisco |
2017-02-23 | PHASE4 |
| NCT03307252 | COMPLETED | Healthy |
Boehringer Ingelheim |
2017-10-25 | PHASE1 |
| NCT02797145 | UNKNOWN | Heart Failure |
Hospital Ana Nery |
2016-05 | PHASE2; PHASE3 |
| NCT02743260 | COMPLETED | Healthy |
University of Cologne |
2016-04 | PHASE4 |
| NCT03131973 | COMPLETED | Rheumatoid Arthritis |
Bristol-Myers Squibb |
2017-05-13 | PHASE1 |
| NCT03197324 | COMPLETED | Type2 Diabetes Mellitus |
Theracos |
2017-07-24 | PHASE1 |
| NCT03136237 | COMPLETED | Hereditary Angioedema |
BioCryst Pharmaceuticals |
2017-02-17 | PHASE1 |
| NCT02915666 | WITHDRAWN | Melanoma |
University of Texas Southwestern Medical Center |
2016-10 | PHASE1 |
| NCT02888327 | COMPLETED | Influenza in Humans |
Alios Biopharma Inc. |
2016-07-31 | PHASE1 |
| NCT03043248 | COMPLETED | Healthy |
Toray Industries, Inc |
2017-02-06 | PHASE1 |
| NCT02740712 | COMPLETED | Neoplasms |
pharmaand GmbH |
2016-04 | PHASE1 |
| NCT02626234 | COMPLETED | cMET-dysregulated Advanced Solid Tumors |
Novartis Pharmaceuticals |
2015-12-08 | PHASE1 |
| NCT02138292 | COMPLETED | Melanoma |
University of Texas Southwestern Medical Center |
2014-07 | PHASE1 |
| NCT02854527 | COMPLETED | Healthy |
Boehringer Ingelheim |
2016-08-22 | PHASE1 |
| NCT02775240 | COMPLETED | Cytomegalovirus (CMV) |
Shire |
2016-07-21 | PHASE1 |
| NCT02762123 | COMPLETED | Rheumatoid Arthritis |
Bristol-Myers Squibb |
2016-05 | PHASE1 |
| NCT01862991 | COMPLETED | Legally Induced Abortion Without Mention of Complication |
Stanford University |
2013-07 | |
| NCT01763931 | COMPLETED | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-01 | PHASE2 |
| NCT02641899 | COMPLETED | Healthy |
Intarcia Therapeutics |
2015-12 | PHASE1 |
| NCT02685462 | COMPLETED | Healthy |
Tobira Therapeutics, Inc. |
2016-01-31 | PHASE1 |
| NCT02578277 | COMPLETED | HIV Infections |
ViiV Healthcare |
2015-11-09 | PHASE1 |
| NCT01887288 | TERMINATED | Metastatic Breast Cancer |
Western Regional Medical Center |
2013-04 | PHASE2 |
| NCT02783040 | COMPLETED | Healthy |
Boehringer Ingelheim |
2015-09-07 | PHASE1 |
| NCT02472236 | COMPLETED | Healthy |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2015-06-08 | PHASE1 |
| NCT02451527 | COMPLETED | Healthy |
First Affiliated Hospital Xi'an Jiaotong University |
2015-05 | PHASE1 |
| NCT02515526 | COMPLETED | AOD Effects and Consequences |
University of Cologne |
2015-06 | |
| NCT02333643 | COMPLETED | Cutaneous Warts |
Maruho Co., Ltd. |
2015-01 | PHASE2 |
| NCT02434861 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
Tesaro, Inc. |
2015-05 | PHASE1 |
| NCT02456844 | COMPLETED | Rheumatoid Arthritis |
Bristol-Myers Squibb |
2015-05 | PHASE1 |
| NCT02106845 | COMPLETED | Neoplasms |
Bayer |
2014-04-22 | PHASE1 |
| NCT02243098 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09-16 | PHASE1 |
| NCT02370615 | COMPLETED | Japanese Healthy Adult Males |
Takeda |
2015-02 | PHASE1 |
| NCT02345304 | WITHDRAWN | Healthy |
Boehringer Ingelheim |
2015-03 | PHASE1 |
| NCT02249910 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2014-09-18 | PHASE1 |
| NCT01398371 | COMPLETED | Heart Failure |
The Alfred |
2011-08 | |
| NCT02231931 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-09-01 | PHASE1 |
| NCT02254148 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-10 | PHASE1 |
| NCT02300350 | COMPLETED | Healthy |
Lexicon Pharmaceuticals |
2014-10 | PHASE1 |
| NCT01951079 | UNKNOWN | Arrhythmia; ECG Changes; Hypotension |
Meir Medical Center |
2013-11 | PHASE3 |
| NCT02227173 | COMPLETED | Drug-drug Interaction Study |
Bristol-Myers Squibb |
2014-09 | PHASE1 |
| NCT01181414 | COMPLETED | Chronic Heart Failure; Cardiomyopathy, Dilated; Atrial Fibrillation |
Hospital Clinic of Barcelona |
2010-10 | PHASE4 |
| NCT02046044 | UNKNOWN | Heart Failure |
Kocaeli University |
2014-01 | PHASE4 |
| NCT02277249 | COMPLETED | Abortion, Induced |
University of California, Los Angeles |
2012-10 | |
| NCT02489786 | COMPLETED | Atrial Fibrillation |
Cairo University |
2012-10 | PHASE4 |
| NCT02273986 | COMPLETED | Healthy |
Kowa Research Institute, Inc. |
2014-08 | PHASE1 |
| NCT02124954 | COMPLETED | Pharmacokinetic Interactions |
Xention Ltd |
2014-05 | PHASE1 |
| NCT01765569 | COMPLETED | Malignant Melanoma, Neoplasms |
Hoffmann-La Roche |
2013-07 | PHASE1 |
| NCT02127034 | COMPLETED | Healthy Subjects; Pharmacokinetics; Drug-Drug Interaction (DDI) |
Astellas Pharma Europe B.V. |
2014-03 | PHASE1 |
| NCT02055703 | COMPLETED | Healthy Subjects |
Eisai Inc. |
2014-01 | PHASE1 |
| NCT02045966 | COMPLETED | Hepatitis C |
Bristol-Myers Squibb |
2014-02 | PHASE1 |
| NCT01775839 | COMPLETED | DRUG REACTIONS |
Seoul National University Hospital |
2013-01 | PHASE4 |
| NCT01897493 | COMPLETED | Healthy Volunteers |
Eli Lilly and Company |
2013-07 | PHASE1 |
| NCT01859078 | COMPLETED | Healthy Volunteers |
Eli Lilly and Company |
2013-05 | PHASE1 |
| NCT01517399 | COMPLETED | Solid Tumors |
Daiichi Sankyo |
2011-12 | PHASE1 |
| NCT01615731 | COMPLETED | Abortion, Induced |
Stanford University |
2012-05 | |
| NCT01162135 | COMPLETED | Prostate Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2010-09 | PHASE2 |
| NCT01701739 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2012-10 | PHASE1 |
| NCT01047748 | COMPLETED | Induced Abortion |
White, Katharine O'Connell, M.D., M.P.H. |
2011-01 | |
| NCT01704638 | COMPLETED | Depression |
Karolinska Institutet |
2008-08 | PHASE1 |
| NCT01598363 | COMPLETED | Healthy Volunteers |
Biogen |
2012-06-30 | PHASE1 |
| NCT01561781 | COMPLETED | Healthy Volunteers |
Sanofi |
2012-03 | PHASE1 |
| NCT01582412 | COMPLETED | Pharmacokinetics of Isavuconazole; Pharmacokinetics of Digoxin; Healthy Volunteers |
Astellas Pharma Global Development, Inc. |
2012-03 | PHASE1 |
| NCT00852787 | UNKNOWN | Hypertension; Hemodialysis |
National Institute on Aging (NIA) |
2009-04 | PHASE4 |
| NCT01583036 | COMPLETED | Epilepsy |
GlaxoSmithKline |
2012-01-16 | PHASE1 |
| NCT01519128 | COMPLETED | Healthy |
Janssen R&D Ireland |
2012-01 | PHASE1 |
| NCT01699776 | COMPLETED | Cardiac Failure |
Cocco, Giuseppe, M.D. |
2008-04 | PHASE4 |
| NCT01477411 | COMPLETED | Drug Interaction Potentiation |
Vifor Pharma |
2011-11 | PHASE1 |
| NCT01357811 | COMPLETED | Healthy Volunteer |
Genzyme, a Sanofi Company |
2011-08 | PHASE1 |
| NCT01436201 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2011-09 | PHASE1 |
| NCT01047566 | COMPLETED | Atrial Fibrillation |
Sanofi |
2010-04 | PHASE4 |
| NCT01355354 | COMPLETED | Healthy Volunteers; Rheumatoid Arthritis |
AstraZeneca |
2011-06 | PHASE1 |
| NCT01288742 | COMPLETED | Hepatitis C Virus |
Tibotec Pharmaceuticals, Ireland |
2011-01 | PHASE1 |
| NCT01306175 | COMPLETED | Healthy |
Boehringer Ingelheim |
2011-02 | PHASE1 |
| NCT01266590 | COMPLETED | Major Depressive Disorder |
Eli Lilly and Company |
2010-12 | PHASE1 |
| NCT00504413 | UNKNOWN | Substance-Related Disorders |
University of Washington |
2007-07 | PHASE1 |
| NCT00281021 | TERMINATED | Carcinoma, Non-Small Cell Lung |
University of Louisville |
2006-02 | PHASE2 |
| NCT01103622 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2010-06 | PHASE1 |
| NCT01147718 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2010-06-11 | PHASE1 |
| NCT00390546 | COMPLETED | Supraventricular Tachycardia |
University of British Columbia |
2006-10 | PHASE3 |
| NCT01134965 | COMPLETED | Healthy |
Boehringer Ingelheim |
2010-06 | PHASE1 |
| NCT01056874 | COMPLETED | Healthy; HIV Infections |
ViiV Healthcare |
2010-03 | PHASE1 |
| NCT01005602 | COMPLETED | Heart Failure |
University of Illinois at Chicago |
2006-12 | PHASE4 |
| NCT00991783 | COMPLETED | Essential Hypertension |
Boryung Pharmaceutical Co., Ltd |
2009-08 | PHASE1 |
| NCT01714206 | COMPLETED | Healthy |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2009-06 | PHASE1 |
| NCT00904176 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-06 | PHASE1 |
| NCT00650910 | COMPLETED | Neoplasms, Breast |
GlaxoSmithKline |
2008-04-23 | PHASE1 |
| NCT00831506 | COMPLETED | Alzheimer Disease; Huntington Disease |
Pfizer |
2009-02 | PHASE1 |
| NCT00860223 | COMPLETED | Healthy |
Puma Biotechnology, Inc. |
2009-04 | PHASE1 |
| NCT00550576 | COMPLETED | Bipolar Disorder |
Rambam Health Care Campus |
2007-10 | PHASE2 |
| NCT00723424 | COMPLETED | Healthy Volunteers; Pharmacokinetics |
AstraZeneca |
2008-07 | PHASE1 |
| NCT01663961 | COMPLETED | Healthy |
Astellas Pharma Europe B.V. |
2008-09 | PHASE1 |
| NCT00712465 | COMPLETED | Atrial Fibrillation |
AstraZeneca |
2008-08 | PHASE1 |
| NCT01082289 | COMPLETED | Schizophrenia |
Sumitomo Pharma America, Inc. |
2008-09 | PHASE1 |
| NCT02182336 | COMPLETED | Healthy |
Boehringer Ingelheim |
2008-06 | PHASE1 |
| NCT02183402 | COMPLETED | Healthy |
Boehringer Ingelheim |
2008-06 | PHASE1 |
| NCT00563732 | COMPLETED | Alzheimer Disease |
Wyeth is now a wholly owned subsidiary of Pfizer |
2007-12 | PHASE1 |
| NCT00158743 | COMPLETED | Pre-eclampsia |
BTG International Inc. |
2004-02 | PHASE2 |
| NCT01518166 | COMPLETED | Diabetes; Healthy |
Novo Nordisk A/S |
2006-05 | PHASE1 |
| NCT02171052 | COMPLETED | Healthy |
Boehringer Ingelheim |
2006-06 | PHASE1 |
| NCT02243553 | COMPLETED | Healthy |
Boehringer Ingelheim |
2006-01 | PHASE1 |
| NCT01514812 | COMPLETED | Healthy; Pharmacokinetic of Digoxin |
Astellas Pharma Inc |
2006-02 | PHASE1 |
| NCT02262520 | COMPLETED | N/A - Healthy Subjects |
Bristol-Myers Squibb |
2006-01 | PHASE1 |
| NCT02172742 | COMPLETED | Epilepsy |
Bial - Portela C S.A. |
2002-05 | PHASE1 |
| NCT00151619 | TERMINATED | Chronic Heart Failure |
Rennes University Hospital |
1999-02-10 | PHASE2 |
| NCT00006330 | COMPLETED | Heart Diseases |
National Center for Research Resources (NCRR) |
||
| NCT00869115 | WITHDRAWN | Heart Failure |
Debiopharm International SA |
2009-06 | PHASE1 |
| NCT00000556 | COMPLETED | Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases |
National Heart, Lung, and Blood Institute (NHLBI) |
1995-03 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2025-04-29)
Check the
Digoxin
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.